Zerbaxa, a new antibiotic of MSD, has been approved by FDA for the treatment of adult bacterial pneumonia

On February 12, 2019, FDA accepted Merck's supplementary new drug application (SNDA) for compound antibiotic product zerbaxa (ceftolozane / tazobactam), and granted the product priority review qualification The artery network (official account: vcbeat) was informed by foreign media that in June 3rd, Mercedes announced that its new antibiotic Zerbaxa had been approved by FDA for approval to treat specific bacterial pneumonia in adults, including hospital acquired bacterial pneumonia (HABP) and ventilator associated pneumonia (VABP) In order to reduce bacterial resistance and ensure the effectiveness of other antibacterial drugs, zerbaxa is currently only approved for the treatment of confirmed pulmonary infection caused by susceptible bacteria Habp and vabp are the second most common nosocomial infectious diseases in the United States They are caused by a variety of different bacteria The most common is Pseudomonas aeruginosa, a gram-negative pathogen The disease is difficult to cure and even takes the lives of patients when it is serious According to a recent publication of the National Institutes of health biomarker Association, the mortality rate of patients with habp ventilation is about 39%, and that of patients with vabp ventilation is about 27% Pneumonia in ventilated patients is still a major clinical challenge, which reflects a high incidence rate and mortality "Antibiotics need to cover a wide range of pathogens, including Pseudomonas aeruginosa, which also makes it more difficult to cure these diseases," said Dr Andrew Shorr, head of respiratory at Washington hospital The approved zerbaxa product is a compound antibiotic, which contains ceftolozane, a cephalosporin antibiotic, and tazobactam, a β - lactamase inhibitor, which can treat habp or vabp caused by a variety of pathogens In the clinical trial of zerbaxa, mosadong conducted a multicenter, double-blind study (nct02070757) on 726 adult patients with habp / vabp The patients were injected with 3G zerbaxa every eight hours for 8 to 14 days, and a control study was conducted with meropenem Compared with meropenem, zerbaxa has a non inferiority effect and can be used as a new therapy for this population At present, the most common complications of taking zerbaxa include diabetes, congestive heart failure and chronic obstructive pulmonary disease, with the incidence of about 22%, 16% and 12% respectively It is worth mentioning that zerbaxa was originally developed by the antibiotic giant Cubist At the end of 2014, MSD purchased Cubist for us $9.5 billion, and the compound antibiotic zerbaxa was naturally included in MSD's bag About Merck, founded in 1891, headquartered in Whitehouse station, New Jersey It is one of the world's largest pharmaceutical companies and a world-renowned leader in healthcare The company focuses on innovative pharmaceutical, life sciences and cutting-edge functional materials technology Merck group has always been driven by technology to create value for patients and customers At present, the company's business is mainly divided into four branches: Merck xuelanuo business branch, consumer health business branch, Merck millipore business branch and functional materials business branch This article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.